MUMBAI: Traditionally Big Pharma has invested and relied on blockbuster drugs, and has not been too keen on research in neglected diseases. But now the scenario may be changing with some companies like GlaxoSmithKline looking at it as a possible strategy for growth in emerging markets, which are growing at a much faster rate (mostly in double digits) as against the developed regions. GlaxoSmithKline, which has blockbusters like respiratory medicines Advair and Avamys, plans to invest around £12m per year (from 2012) in its albendazole drug programme for treating children with intestinal worms in Africa and India.
Read more: 'Malaria vaccine in final trials' - The Times of India http://timesofindia.indiatimes.com/business/india-business/Malaria-vaccine-in-final-trials/articleshow/6938098.cms#ixzz15VIGV7ry
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment